← Back to Clinical Trials
Recruiting Phase 2 NCT06287619

Post-operative Intravenous Iron to Treat Iron-deficiency Anemia in Patients Undergoing Cardiac Surgery

◆ AI Clinical Summary
Plain-language summary for patients

Trial Parameters

Condition Chronic Iron Deficiency Anaemia
Sponsor University Health Network, Toronto
Study Type INTERVENTIONAL
Phase Phase 2
Enrollment 60
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2025-04-03
Completion 2026-12
Interventions
Monoferric Injectable Product0.9% sodium chloride solution

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

POAM is a multicenter, randomized, controlled, internal pilot trial, using a conventional, parallel group, two-armed design at 3 cardiac surgery centres in Canada. The study is designed to assess the feasibility of a future, definitive RCT investigating whether, in patients with chronic iron-deficiency anemia undergoing cardiac surgery, IV iron therapy in the postoperative period (initiated shortly after surgery, and repeated at 42 days after surgery, if needed) improves clinical outcomes (days alive and out of hospital at 90 days after surgery; DAOH-90) relative to placebo.

Eligibility Criteria

Inclusion Criteria: Patients who are undergoing any non-emergency open cardiac surgery and who meet all following criteria: 1. Age greater than 18 years old 2. Preoperative iron-deficiency with or without anemia (defined as Hb \<130 g/L) with any one of: 1. ferritin ≤100 μg/l; or 2. ferritin ≤ 300 μg/L and transferrin saturation ≤ 20%; or 3. reticulocyte Hb content \< 29 pg, where available Exclusion Criteria: Patients who meet any of the following criteria are not eligible for the study: 1. specialized procedures (e.g., ventricular assist device insertion, thoracoabdominal aneurysm, complex adult congenital surgery and heart transplant) 2. established contraindications to IV iron: 1. hypersensitivity to the iron product 2. history of \>2 food and/or drug allergic reactions (excluding drug intolerance) 3. non-iron deficiency anemias such as myelodysplastic syndrome 4. history of iron overload or disturbances in use of iron such as hemochromatosis or hemosiderosis 5. decompensated liver

Related Trials

}
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology